John DeMattei

Directeur des opérations chez OnKure, Inc.

Health Technology

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Anthony D. Piscopio	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	13 ans
Xuedong Liu	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	13 ans
R. Carruthers	M	66	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	5 ans
Nicholas A. Saccomano	M	65	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	-
Isaac Manke	M	47	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	3 ans
Andrew Phillips	M	53	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	3 ans
Guobao Zhao	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	7 ans